Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop
Journal Title: The AAPS Journal - Year 2011, Vol 13, Issue 2
Abstract
There have been some successes in qualifying biomarkers and applying them to drug development and clinical treatment of various diseases. A recent success is illustrated by a collaborative effort among the US Food and Drug Administration, the European Medicines Agency, and the pharmaceutical industry to provide a set of seven preclinical kidney toxicity biomarkers for drug development. Other successes include, but are not limited to, clinical biomarkers for cancer treatment and clinical management of heart transplant patients. The value of fully qualified surrogate endpoints in facilitating successful drug development is undisputed, especially for diseases in which the traditional clinical outcome can only be assessed in large, multi-year trials. Emerging biomarkers, including chemical genomic or imaging biomarkers, and measurement of circulating tumor cells hold great promise for early diagnosis of disease and as prognostic tests for managing treatment of chronic diseases such as osteoarthritis, Alzheimer disease, cardiovascular disease, and cancer. To advance the success of treating and managing these diseases, efforts are needed to establish the temporal relationship between changes in inflammatory or imaging biomarkers with the progression of the chronic disease, and in the case of cancer, between the extent of circulating cancer cells and tumor progression or remission.
Authors and Affiliations
Jane P. F. Bai, Robert Bell, ShaAvhree Buckman, Gilbert J. Burckart, Hans-Georg Eichler, Kenneth C. Fang, Federico M. Goodsaid, William J. Jusko, Lawrence L. Lesko, Bernd Meibohm, Scott D. Patterson, Oscar Puig, Jeffrey B. Smerage, Barbara J. Snider, John A. Wagner, Jingsong Wang, Marc K. Walton, Russell Weiner
Keywords
Related Articles
- EP ID EP681316
- DOI 10.1208/s12248-011-9265-x
- Views 62
- Downloads 0
The role of halogen substitution in classical cannabinoids: A CB1 pharmacophore model
The presence of halogens within the classical cannabinoid structure leads to large variations in the compounds' potencies and affinities for the CB1 receptors. To explore the structure activity relationships within this...
Development and characterization of biodegradable chitosan films for local delivery of paclitaxel
Intratumoral and local drug delivery strategies have gained momentum recently as a promising modality in cancer therapy. In order to deliver paclitaxel at the tumor site in therapeutically relevant concentrations, chitos...
Microdialysis as a tool in local pharmacodynamics
In many cases the clinical outcome of therapy needs to be determined by the drug concentration in the tissue compartment in which the pharmacological effect occurs rather than in the plasma. Microdialysis is an in vivo t...
Challenges in the transition to model-based development
Metabolic Cleavage and Translocation Efficiency of Selected Cell Penetrating Peptides: A Comparative Study with Epithelial Cell Cultures
We investigated the metabolic stability of four cell penetrating peptides (CPPs), namely SAP, hCT(9-32)-br, [Pα] and [Pβ], when in contact with either subconfluent HeLa, confluent MDCK or Calu-3 epithelia...